Dear Colleagues,
The Society for Immunotherapy of Cancer (SITC) is now ready to welcome more than 4,000 attendees at our 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) in Washington, D.C., on Nov. 7-11, 2018. The SITC 2018 team has worked for more than a year to present exemplary scientific and educational programs during our five-day annual conference that covers the breadth of basic, translational and clinical of cancer immunotherapy. The cutting-edge science being presented begins with the Industry Committee program on mechanisms of immune escape. The highly-attended primer serves as a refresher course for many professionals, while a new workshop on the microbiome in cancer therapy will lead into the meeting. These Pre-Conference Programs are Nov. 7-8.
The SITC Annual Meeting (from Nov. 9-11) is the premier venue for all aspects of immunotherapeutic research, and this year is no exception. There will be state-of-the-art immunotherapy clinical trial presentations that have the potential to change practice, and sessions will include T cell immunology, the tumor microenvironment and engineering the next-generation of immunotherapeutic agents. I wanted to remind you about the outstanding 2018 SITC Smalley Award Winner, Philip D. Greenberg, MD, (Fred Hutchinson Cancer Research Center), who will discuss research on advancing cellular immunotherapies first thing Saturday morning. The Friday morning Keynote presentation from Nicholas P. Restifo, MD, (National Cancer Institute) will, no doubt, be excellent.
We must remember that all work and no play can make us quite dull indeed! The CheckPoints Party, the annual concert and gathering of the SITC family featuring our very own house band, is scheduled for 8:30 p.m. on Saturday, Nov. 10, 2018, in the Marriott Marquis Liberty Ballroom. Many of your favorite leaders in the field (now featuring a Nobel Prize awardee!) will play rock and blues hits. I’ll see you all there!
Sincerely,
Lisa H. Butterfield, PhD
SITC President
P.S. Because SITC expects our highest attendance yet for an Annual Meeting, I’m encouraging attendees to pick up your badge and materials the night before your first program, to avoid the early morning onsite registration lines. SITC 2018 onsite registration begins on Wednesday, Nov. 7, from 10 a.m. – 8 p.m., at L St. Bridge of the Walter E. Washington Convention Center. Badge pick-up is also available from 6:30 a.m. – 7 p.m. on Friday and Saturday, and a brief period on Sunday morning.
Update About SITC 2018 Registration
We wanted you to be aware that the SITC office has received communication about fraudulent emails, phone calls and offers people have received regarding our 33rd Annual Meeting & Pre-Conference Programs (SITC 2018).
We want to ensure you’re aware of how to safely register for the event through the official website (if you’ve not done so already), and so that you’ll be able to confirm the communication you receive is from valid sources.
Official registration for the 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) is available here: https://www.sitcancer.org/2018/attendee-resources/registration.
Please direct all registration-related questions to SITC@showcare.com or 1-866-320-3203.
All official forthcoming registration information will come from “Showcare," (SITC@showcare.com) SITC 2018’s official registration partner.
If you have further questions, please contact SITC at events@sitcancer.org or 414-271-2456.
Daily Highlights of the 33rd Annual Meeting & Pre-Conference Programs
Join SITC and your colleagues for five days of scientific exchange, education and networking at the 33rd Annual Meeting & Pre-Conference Programs (SITC 2018). Beginning Nov. 7, 2018, SITC 2018 will feature engaging, high quality programming for audiences of all professional backgrounds.
Below is a daily overview of programming. Click the links to learn more about the program, and then click here to view the complete SITC 2018 schedule.
Wednesday, Nov. 7, 2018
Thursday, Nov. 8, 2018
Friday, Nov. 9, 2018
Saturday, Nov. 10, 2018
Sunday, Nov. 11, 2018
Attend the FDA and SITC Co-Sponsored Workshop: Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials
SITC is pleased to announce a co-sponsored workshop with the U.S. Food and Drug Administration (FDA) on Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials. This free, innovative workshop will take place from 2–6 p.m. on Nov. 8, 2018, in Washington, D.C., at the Walter E. Washington Convention Center.
The goals of this workshop include:
- To provide a forum for open discussion among academia, industry, international regulatory bodies, payers and patient groups to evaluate current methods for assessing efficacy of cancer immunotherapeutics and identify opportunities for advancing immune-modified, tumor measurement-based efficacy endpoint data to support regulatory, clinician, and patient decision making
- To ensure the leading experts in cancer immunotherapeutics have an opportunity to evaluate international efforts to standardize immune-modified response criteria in cancer trials
- To seek feedback from stakeholders on current FDA thinking regarding use of immune-modified response criteria in the assessment of tumor measurement-based endpoints in development programs of cancer immunotherapeutics
Workshop Organizers:
- Michael B. Atkins, MD – Georgetown – Lombardi Comprehensive Cancer Center
- Howard L. Kaufman, MD, FACS – Replimune Group Inc.
- Samir N. Khleif, MD – Georgetown University
- Ke Liu, MD, PhD – CBER, FDA
- Marc Theoret, MD – Office of Hematology and Oncology Products, FDA
This workshop is intended for stakeholders interested in immunotherapeutic cancer drug development including, international academia, industry, regulatory agencies, consulting firms, payer groups and patient groups.
Click here to learn more about this workshop and register to attend.